Join
Live feed
·
PRReleasevia Quantisnow
Immuneering Corporation logo

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

ByQuantisnow·Wall Street's wire, on your screen.
IMRX· Immuneering Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMRX (Immuneering Corporation) and more on Quantisnow.